Onco Actu du 20 janvier 2016

	2.5 Etiologie - Gènes
Scientists find new gene fault behind ovarian cancer [Cancer Research UK] Women who carry an inherited fault in the gene BRIP1 are over three times more likely to develop ovarian cancer than those without the fault, according to a study published in the Journal of the National Cancer Institute.
	2.7 Etiologie - Obésité
Researchers investigate why obesity can trigger bowel cancer [NHS Choices] This latest study, conducted in genetically engineered mice, found that obesity caused by a diet rich in fats or carbohydrates "silenced" a hormone called guanylin. This, in turn, led to the turning off of a receptor called guanylyl cyclase C (GUCY2C) found on cells that line the bowel.
	3. Prévention
Camembert kills cancer? Cheesy headlines distort preliminary rat study [HealthNewsReview] The headlines about a study from the University of Michigan stink worse than a block of ripe Limburger and have more holes than a wheel of Swiss.
	5.12 Immunothérapies
Engineering a cancer-fighting immune super soldier [Cancer Research UK] Let’s have a look at the promise – and challenges – of engineered T-cell therapy.
	5.2.1 Pharma - Partenariats
Cellectis Enters into New Agreement with CELLforCURE for the cGMP Manufacturing of UCART123 for Hematological Malignancies [Cellectis] Following the recent successful production of UCART19, pursuant to this second agreement CELLforCURE will be responsible for the manufacturing of cGMP clinical batches for UCART123, the lead engineered T-cell product candidate in Cellectis’ wholly owned portfolio.
	5.2.3 Pharma - économie
Love 'Em? Hate 'Em? No Matter. The Drug Industry Gets What It Wants. [Xconomy] Here’s a list of big wins for the industry since George W. Bush took office; it would suggest that the public’s thumbs-down and a few political slings and arrows are not what matters.
	5.3.4 Traitements - AMM (FDA, EMA)
FDA grants priority review status to Eisai’s sNDA for anticancer drug lenvatinib [Pharmaceutical Business Review] The sNDA was based on a phase II clinical trial that compared the safety and efficacy among three groups.
Genmab Announces U.S. FDA Approval of Arzerra® (ofatumumab) as Extended Treatment for Recurrent or Progressive CLL [Genmab] Approval based on data from interim analysis of Phase III PROLONG study.
	5.5 ASCO
Data for KEYTRUDA® (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium [Merck] Seven Registration-Enabling Trials Evaluating KEYTRUDA in Patients with Gastrointestinal Cancers are Planned or Underway.
NewLink Genetics Corporation to Present Phase 1b Data on Indoximod in Combination Therapy in Patients With Metastatic Pancreatic Cancer at ASCO GI [NewLink Genetics] Indoximod is an orally available small molecule that has shown the potential to interfere with multiple targets within the indoleamine 2,3-dioxygenase (IDO) pathway. It is designed to be used in combination with other therapeutic agents to maximize the body's immune response against a range of tumor types.
	6.1 Observation
Dying US cancer patients more likely to face expensive care [STAT] The study analyzed health records of more than 389,000 cancer patients in the United States, Canada, Belgium, the Netherlands, England, Germany, and Norway over the last six months of their lives.
	6.10 Politiques
In Davos, Joe Biden asks for help making case for moonshot [STAT] In Davos, Switzerland, at the World Economic Forum Tuesday attended by top federal officials and scientists, Biden emphasized that he saw his job as educating the public about what needs to be done.
AACR Provides Thought Leadership to Vice President Biden During Special Session on Fighting Cancer at Davos [AACR] The special roundtable session convened by Vice President Biden and moderated by Francis S. Collins, MD, PhD, director of the National Institutes of Health (NIH), brought together international leaders in cancer research, cancer treatment, and data science to discuss potential opportunities to advance the pace of progress in the fight against cancer.
Leading Cancer Experts Comment on the Cancer Initiative in the State of the Union Address [CANCER RESEARCH Catalyst] See what these cancer research experts have to say about the pronouncement, and what the organization wants to do to contribute to this initiative...
Biden pledges faster U.S. approval for cancer drug cocktails [Reuters] Biden said he had hosted a meeting at his home with three unnamed large drug companies and the head of the U.S. Food and Drug Administration (FDA) at which both sides had pledged to do more to get novel cancer drug cocktails to patients.
	6.6 Publications
Requesting clinical trial protocols [BMJ Blogs] We have recently made some changes to our submission system. If we receive a clinical trial, we will now ask that authors include the original trial protocol. Editor-in-chief, Dr Trish Groves, explains why...
Research gets increasingly international [Nature News & Comment] Big US report documents increases in international collaboration and Chinese science output.
	6.7.3 DMP
Startup CrossChx Says It Is Building Crucial Missing Plumbing for America’s Health-Care System [MIT Technology Review] A startup uses encryption and fingerprint authentication to compare medical records across providers—and aims to make them easier to move, too.